Table 9.
Outcome | N | hPDI versus PDI statistical significance with outcome | hPDI versus uPDI statistical significance with outcome | Studies (references) | ||||
---|---|---|---|---|---|---|---|---|
Favors hPDI* | Both same† | Favors PDI‡ | Favors hPDI* | Both same† | Favors uPDI‡ | |||
Gestational diabetes | 2 | 0 | 1 | 1 | 0 | 2 | 0 | (31, 106) |
HOMA-IR | 1 | 1 | 0 | 0 | 1 | 0 | 0 | (89) |
QUICKI | 1 | 0 | 1 | 0 | 0 | 1 | 0 | (89) |
Serum insulin | 2 | 1 | 0 | 1 | 2 | 0 | 0 | (24, 89) |
Type 2 diabetes | 5 | 2 | 3 | 0 | 4 | 0 | 0 | (30, 36, 53, 57, 96) |
Hemoglobin A1c | 1 | 0 | 1 | 0 | 0 | 1 | 0 | (26) |
HOMA-IR, homeostatic model assessment of insulin resistance; PDI, plant-based dietary index; hPDI, healthful PDI; uPDI, unhealthful PDI; QUICKI, quantitative insulin sensitivity check index. *Favors hPDI if hPDI hazard ratio statistical significance for the outcome is more favorable than the comparator (PDI or uPDI): e.g., hPDI significantly favorable and comparator non-significant or unfavorable, or hPDI non-significant and comparator unfavorable. †Both same if hPDI hazard ratio has same relationship to outcome as comparator (both significantly favorable, both non-significant, or both significantly unfavorable). ‡Favors comparator (PDI or uPDI) if hazard ratio statistical significance for the outcome is more favorable than the hPDI: e.g., comparator significantly favorable and hPDI non-significant or unfavorable, or comparator non-significant and hPDI unfavorable.